WVE (Wave Life Sciences) Total Stockholders Equity: $453.52 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WVE Wave Life Sciences Inc WVE
60 GF Score
Price $5.21
GF Value $3.96
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Wave Life Sciences Total Stockholders Equity?

Wave Life Sciences WVE -1.61% 60 Total Stockholders Equity is $453.52 Mil as of Jun. 2026. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $3.96 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Wave Life Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $453.52 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Wave Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 was $2.35. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Wave Life Sciences's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.10.

Wave Life Sciences  (NAS:WVE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Wave Life Sciences's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(453.52-0)/193.278
=2.35

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Wave Life Sciences's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.508 + 40.082) / 453.52
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wave Life Sciences Total Stockholders Equity Related Terms

Wave Life Sciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Wave Life Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wave Life Sciences Total Stockholders Equity Chart

Wave Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.50 -45.09 39.63 209.52 518.36

Wave Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.27 124.55 518.36 511.73 453.52
WVE
60GF Score
Wave Life Sciences Inc WVE
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $453.52 Mil mean?
Wave Life Sciences (WVE) has a Total Stockholders Equity of $453.52 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Wave Life Sciences and its competitors.
Is Wave Life Sciences' Total Stockholders Equity too high?
Wave Life Sciences' current Total Stockholders Equity is $453.52 Mil. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' Total Stockholders Equity compare to FBRX and SVRA?
Wave Life Sciences' Total Stockholders Equity of $453.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Wave Life Sciences and its competitors. Wave Life Sciences's current Total Stockholders Equity is $453.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.96, compared to a current price of $5.21 — trading 31.4% above its estimated fair value. The current Total Stockholders Equity is $453.52 Mil. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current Total Stockholders Equity is $453.52 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wave Life Sciences (WVE) Overvalued in 2026?

Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued. The current stock price of $5.21 is trading 31.4% above its estimated GF Value™ of $3.96. GuruFocus considers Wave Life Sciences to be Significantly Overvalued.

Key valuation signals for WVE:

  • Total Stockholders Equity: $453.52 Mil
  • GF Value™: $3.96 vs. price of $5.21 (31.4% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wave Life Sciences Business Description

Other Exchanges 1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score

Get the complete analysis for WVE

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.21
Price
$3.96
GF Value